These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 34052717)
21. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
22. 2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition. Romagnoli R; Kimatrai Salvador M; Schiaffino Ortega S; Baraldi PG; Oliva P; Baraldi S; Lopez-Cara LC; Brancale A; Ferla S; Hamel E; Balzarini J; Liekens S; Mattiuzzo E; Basso G; Viola G Eur J Med Chem; 2018 Jan; 143():683-698. PubMed ID: 29220790 [TBL] [Abstract][Full Text] [Related]
23. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression. Lu Y; Feng Y; Li Z; Li J; Zhang H; Hu X; Jiang W; Shi T; Wang Z Eur J Med Chem; 2022 Jan; 227():113908. PubMed ID: 34656900 [TBL] [Abstract][Full Text] [Related]
24. A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors. Barnes NG; Parker AW; Ahmed Mal Ullah AA; Ragazzon PA; Hadfield JA Bioorg Med Chem; 2020 Oct; 28(19):115684. PubMed ID: 32912434 [TBL] [Abstract][Full Text] [Related]
25. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma. Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690 [TBL] [Abstract][Full Text] [Related]
26. Imidazo[1,2-a]quinoxalines for melanoma treatment with original mechanism of action. Patinote C; Deleuze-Masquéfa C; Kaddour KH; Vincent LA; Larive R; Zghaib Z; Guichou JF; Assaf MD; Cuq P; Bonnet PA Eur J Med Chem; 2021 Feb; 212():113031. PubMed ID: 33309473 [TBL] [Abstract][Full Text] [Related]
27. Design, synthesis, and evaluations of the antiproliferative activity and aqueous solubility of novel carbazole sulfonamide derivatives as antitumor agents. Sun L; Wang C; Hu X; Wu Y; Jiang Z; Li Z; Chen X; Hu L Bioorg Chem; 2020 Jun; 99():103766. PubMed ID: 32247110 [TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site. Liu YN; Wang JJ; Ji YT; Zhao GD; Tang LQ; Zhang CM; Guo XL; Liu ZP J Med Chem; 2016 Jun; 59(11):5341-55. PubMed ID: 27172319 [TBL] [Abstract][Full Text] [Related]
29. Discovery of Novel Diaryl-Substituted Fused Heterocycles Targeting Katanin and Tubulin with Potent Antitumor and Antimultidrug Resistance Efficacy. Jiang F; Yu M; Liang Y; Ding K; Wang Y J Med Chem; 2024 Jul; 67(14):12118-12142. PubMed ID: 38996194 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: Potent inhibitors of angiogenesis and tubulin polymerization. Sun M; Zhang Y; Qin J; Ba M; Yao Y; Duan Y; Liu H; Yu D Bioorg Chem; 2021 Aug; 113():104988. PubMed ID: 34034135 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and evaluation of new 2-chloro-4-aminopyrimidine and 2,6-dimethyl-4-aminopyrimidine derivatives as tubulin polymerization inhibitors. Xu S; An B; Li Y; Luo X; Li X; Jia X Bioorg Med Chem Lett; 2018 Jun; 28(10):1769-1775. PubMed ID: 29673981 [TBL] [Abstract][Full Text] [Related]
32. Discovery of new LXRβ agonists as glioblastoma inhibitors. Chen H; Chen Z; Zhang Z; Li Y; Zhang S; Jiang F; Wei J; Ding P; Zhou H; Gu Q; Xu J Eur J Med Chem; 2020 May; 194():112240. PubMed ID: 32248003 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223 [TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and bioevaluation of pyrazolo[1,5-a]pyrimidine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site with potent anticancer activities. Li G; Wang Y; Li L; Ren Y; Deng X; Liu J; Wang W; Luo M; Liu S; Chen J Eur J Med Chem; 2020 Sep; 202():112519. PubMed ID: 32650183 [TBL] [Abstract][Full Text] [Related]
35. 1,3,4-oxadiazole-2-thione Derivatives; Novel Approach for Anticancer and Tubulin Polymerization Inhibitory Activities. Abdel-Aziz M; Metwally KA; Gamal-Eldeen AM; Aly OM Anticancer Agents Med Chem; 2015; 16(2):269-77. PubMed ID: 26343141 [TBL] [Abstract][Full Text] [Related]
36. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654 [TBL] [Abstract][Full Text] [Related]
37. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172 [TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationship studies and in vitro and in vivo anticancer activity of novel 3-aroyl-1,4-diarylpyrroles against solid tumors and hematological malignancies. Puxeddu M; Shen H; Bai R; Coluccia A; Nalli M; Mazzoccoli C; Da Pozzo E; Cavallini C; Martini C; Orlando V; Biagioni S; Mazzoni C; Coluccia AML; Hamel E; Liu T; Silvestri R; La Regina G Eur J Med Chem; 2020 Jan; 185():111828. PubMed ID: 31727471 [TBL] [Abstract][Full Text] [Related]
39. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778 [TBL] [Abstract][Full Text] [Related]
40. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia. Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]